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Multiple toxin production in the cyanobacterium microcystis:
isolation of the toxic protease inhibitor cyanopeptolin 1020
Abstract
The isolation and structure of cyanopeptolin 1020 (hexanoic
acid-Glu-N[-O-Thr-Arg-Ahp-Phe-N-Me-Tyr-Val-]) from a Microcystis strain is reported. Very potent
picomolar trypsin inhibition (IC(50) = 670 pM) and low nanomolar values against human kallikrein (4.5
nM) and factor XIa (3.9 nM) have been determined for cyanopeptolin 1020. For plasmin and
chymotrypsin, low micromolar concentrations were necessary for 50% inhibition. Cyanopeptolin 1020
was found to be toxic against the freshwater crustacean Thamnocephalus platyurus (LC(50) = 8.8
microM), which is in the same range as some of the well-known microcystins. These data support the
hypothesis that cyanopeptolins can be considered as a second class of toxins in addition to the
well-established microcystins in Microcystis.
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The isolation and structure of cyanopeptolin 1020 (hexanoic acid-Glu-N[–O–Thr-
Arg-Ahp-Phe-N-Me-Tyr-Val-]) from a Microcystis strain is reported. Very potent 
picomolar trypsin inhibition (IC50 = 670 pM) and low nanomolar values against 
human kallikrein (4.5 nM) and factor XIa (3.9 nM) have been determined for 
cyanopeptolin 1020. For plasmin and chymotrypsin, low micromolar concentrations 
were necessary for 50% inhibition. Cyanopeptolin 1020 was found to be toxic against 
the freshwater crustacean Thamnocephalus platyrus (LC50 = 8.8 µM), which is in the 
same range as some of the well-known microcystins. These data support the 
hypothesis that cyanopeptolins can be considered as a second class of toxins in 
addition to the well-established microcystins in Microcystis. 
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Cyclic depsipeptides containing the structural element 3-amino-6-hydroxy-2-
piperidone (AHP) (so-called cyanopeptolins) are widely distributed secondary 
metabolites in cyanobacteria.1 The structural diversity of previously described 
compounds is large, but all can be considered inhibitors of serine proteases of 
crustaceans and mammals.1 Although preferentially mammalian enzymes in the 
context of pharmacological research have been tested, the evolutionary primary target 
enzymes can be assumed to be those of aquatic invertebrates that are important 
grazers of these cyanobacteria.1 Digestive serine proteases of these invertebrates are 
strongly inhibited2 and could thus render the cyanobacteria unsuitable food for them. 
The conserved feature of serine proteases in evolution allows these inhibitors to be 
successfully applied also against mammalian enzymes. Most of the AHP-containing 
compounds are active in the micromolar range,1c but some fit so perfectly in the 
reaction center of mammalian serine proteases that nanomolar concentrations were 
shown to be sufficient for inhibition.3 Co-crystallization experiments have been 
conducted to analyze in atomic detail the binding properties of such an inhibitor to the 
reaction center of mammalian trypsin.4 While the inhibition of digestive serine 
proteases of various organisms is well established, on the acute toxicity of some of 
these congeners is not understood. Microcystilide A when applied intraperitoneally to 
mice induced convulsions and spasms but not death.5 Cyanopeptolin SS isolated from 
a natural cyanobacterial bloom caused death of crustaceans6 as did oscillapeptin J for 
Thamnocephalus platyurus.7 
While little is known about the toxicity of cyanopeptolins, the most studied 
cyanobacterial toxins are the microcystins, which exert their hepatotoxicity through 
protein phosphatase inhibition8 and are produced by species of the genera 
Microcystis, Anabaena, Oscillatoria, Planktothrix, and Nostoc. Microcystins are 
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suspected of countless animal poisonings throughout the globe and also thought to be 
responsible for a severe incident in Brazil, where several persons died of 
contaminated water.9 As a direct consequence, the World Health Organization set 
guidelines for drinking water and defined threshold values for microcystin 
concentration.9 However, cyanobacteria of the genus Microcystis are known to 
produce several classes of compounds in addition to the microcystins frequently 
totaling more than 10 distinct secondary metabolites. For example, Microcystis 
aeruginosa PCC 7806 is known to produce cyanopeptolins A-D, cyanopeptolin 963A, 
[D-Asp3]microcystin-LR and microcystin-LR, and the aerucyclamides A-D.10  While 
most of the attention on toxic cyanobacterial peptides focused on the microcystins, the 
above mentioned reports on toxic effects of cyanobacteria might imply the presence 
of additional toxins related to cyanopeptolins in Microcystis. Thus, one could propose 
that potent and unselective trypsin inhibitors are able to shut down other processes 
than protein digestion by virtue of their binding to other serine proteases. 
Here we report on an extremely potent, picomolar trypsin inhibitor, cyanopeptolin 
1020 (1), which also binds in the low nanomolar range to factor XIa and human 
kalllikrein. In addition, this compound exhibits acute toxic properties against the 
crustacean Thamnocephalus platyurus. In addition to several microcystins found in 
the producing strain, cyanopeptolin 1020 (1) constitutes a second toxic compound 




























































The 60% methanolic extract of the biomass of Microcystis aeruginosa UV-006 was 
fractionated and assayed against the sensitive freshwater crustacean Thamnocephalus 
platyurus for acute toxicity. Overall, more than 20 different compounds were present 
in these fractions, and out of totally 16 fractions, nine were found to display acute 
toxicity in this assay. Among these nine fractions, eight compounds were assigned as 
known or new microcystins (Table S1, see supporting information). So far 
microcystins of all Microcystis strains have been shown to contain the structural 
element N-methyldehydroalanine rather than the isomeric dehydrobutyrine. Under 
this presumption, we found the very common and typical microcystin congeners 
[Asp3]-MC-LR and MC-LR. MC-LR and MC-LA have already been described in a 
previous study on this strain11 and we could confirm both components. In addition, we 
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found the lipophilic congeners MC-LAba, MC-LA, MC-LV and MC-LL which were 
only rarely reported before.12  Additionally, two new variants were found (assigned 
based on typical absorption and mass spectra), which have not been described yet (see 
table S1, supporting information). However, the amounts available were too small to 
allow the determination of the structure. 
Interestingly, one compound displayed similar toxicity as MC-LA, but based on the 
UV spectrum, it was hypothesized that this compound is not a microcystin, but a 
structurally different peptide. In order to elucidate the structure of this toxin, this 
fraction was purified and analyzed by NMR spectroscopy and chemical degradation 
(amino acid analysis). The molecular formula of 1 was determined to be 
C50H72N10O13 based on HRMS complemented by isotope labeling studies that 
established the presence of 10 N atoms. This molecular formula was consistent with 
the NMR data (Table 1). The 1H NMR spectrum displayed the typical pattern of a 
peptide. The different amino acids were identified based on 1H,1H COSY, 1D-
TOCSY and HMBC data as Glu, Thr, Arg, Ahp, Phe, N-Me-Tyr, Val and hexanoic 
acid (HA), see also the supporting information for full details. The sequence was 
obtained by 1H-13C long-range correlations: From Glu-NH to HA-C1, from Thr-NH 
to Glu-C1, from Arg-NH to Thr-C1, from Thr-H3 to Val-C1, from Val-NH to N-Me-
Tyr-C1, from N-Me-Tyr-NCH3 to Phe-C1 and from Ahp-NH to Arg-C1. The 
macrocyclic ring was established by a ROESY interaction between Ahp-H5 and Phe-
H3a, and Ahp-NH and Arg-H2 (Figure 1). This sequence assignment was 
corroborated by elaborate MS experiments of both natural abundance and 15N 
enriched peptides. The mass fragmentation pattern of cyanopeptolin 1020 (1) has 
been found previously in complex mixtures by MALDI-TOF MS. 2b The fragment ion 
at m/z = 904 results from the loss of the hexanoyl fragment (Hex) and water. 
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Moreover, the detection of a peak at m/z = 794 (containing 9 N atoms) 
is corresponding to the loss of the Hex-Glu side chain. The fragment ion at m/z  =  
467 (6 N atoms) was assigned to the fragment Hex-Glu-dehydrobutyrate-Arg 
resulting from cleavage of the peptide bond C-terminal at Arg and dehydration of the 
Thr residue. The complementary fragment Ahp-Phe-N-Me-Tyr-Val-OH(-H2O) (m/z = 
534) could also be detected. The mass detected at m/z = 420 (containing 3 N atoms) 
was assigned to the Phe-N-Me-Tyr-Val-OH (-H2O) fragment. Based on this evidence 






Figure 1. Key COSY, ROESY and HMBC correlations in cyanopeptolin 1020 (1). 
 
 
The configuration of 1 was determined by hydrolysis and the enantiomers were 
separated following Marfey’s method. This procedure established the configuration of 
the amino acids as L-Glu, L-Thr, L-Val, L-N-Me-Tyr, L-Phe and L-Arg. For the Ahp 
residue, the relative configuration was assigned based on ROESY interactions 
between Ahp-NH and Ahp-H3a, Ahp-H3a and Ahp-OH, Ahp-H2 and Ahp-H3b, Ahp-
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H2 and Ahp-4a. Therefore, the OH group is positioned in a pseudo axial position, 
which can be explained by the anomeric effect. The absolute configuration of the Ahp 
residue was established by oxidation with CrO3,
  followed by hydrolysis and Marfey’s 
derivatization to yield L-Glu.  
Cyanopeptolin 1020 (1) belongs to a large group of related cyclodepsipeptides that 
feature the Ahp residue as a key structural unit.1 These peptides have been described 
in the literature as protease inhibitors, where basic amino acids adjacent to Ahp such 
as Arg or Lys convey selectivity for trypsin, and hydrophobic amino acids result in 
chymotrypsin selectivity. We have evaluated the inhibitory activity of cyanopeptolin 
1020 for trypsin, chymotrypsin and several other proteases involved in blood 
coagulation (Table S2, supporting information). Cyanopeptolin 1020 inhibited trypsin 
with an IC50 value of 0.67 nM. This potent inhibitory power against trypsin is 
remarkable, and it represents one of the strongest and most potent Ahp-containing 
inhibitors that have been isolated to date. When compared to A90720A3  (IC50 = 10 
nM against bovine trypsin), cyanopeptolin 1020 (1) features a Phe residue instead of a 
Val, and the side chain D-Leu/sulfated glycerate is replaced by a L-Glu/hexanoic acid 
combination. Based on the crystal structure of the A90720A/bovine trypsin complex 
(PDB code 1TPS),4 we docked cyanopeptolin 1020 into the active site of bovine 
trypsin (AutoDock 4.0).13 Conformational searching followed by docking converged 
to the general conformation shown in Figure 2 (Cyanopeptolin 1020, green; 
A90720A, grey). The basic interactions for 1 with bovine trypsin match the one found 
in the crystal structure: the Arg side-chain recognizes the P1 binding site, and the Ahp 
residue modulates the conformation of the side chains of the catalytic triad Asp-His-
Ser. It has been suggested by structural work by two groups3,14 that Ahp-containing 
inhibitors prevent a water molecule from being close to the scissile bond. The sulfated 
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glycerate residue is replaced by Glu in 1 and the Phe residue occupies the same 
position as Val in the 1TPS structure. However, the presence of the bulky Phe residue 
in lieu of Val forces the N-Me-Tyr residue inward, which might result in a more 
favorable interaction with trypsin, and thus in increased binding. 
 
Figure 2. Crystal structure of A90720A (grey) /bovine trypsin complex (PDB code 1TPS) with cyanopeptolin 
1020 (1, green) docked into the active site. 
In addition to the IC50 value of depsipeptide 1 against trypsin in the picomolar 
range, low nanomolar IC50 values against factor XIa (3.9 nM) and kallikrein (4.5 nM) 
were determined. For plasmin and chymotrypsin, IC50 values of 0.49 and 1.8 M, 
respectively, could be measured. We did not find inhibitory properties against the 
human plasminogen activator, thrombin and human LMW urokinase at concentrations 
below 2.5 µM. Although these values cannot be directly compared with each other, as 
different enzymes, different substrates and different concentrations have been used in 
the experiments, generally very potent inhibition values have been used. Therefore, 
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these values confirm that the cyanopeptolin 1020 (1) is a potent inhibitor of a series of 
serine proteases. 
Additionally, we wanted to confirm the toxicity of cyanopeptolin 1020 (1) against 
the sensitive freshwater crustacean Thamnocephalus platyurus using the highly 
purified cyanopeptolin 1020 (1). T. platyurus serves as a benchmark organism for the 
evaluation of the ecotoxicological potential of natural products.15 We have determined 
an LC50 value of 8.8 M in the 24-h acute toxicity assay (Figure S14, supporting 
information). This value is comparable to those determined for microcystins, which 
represent the prototype example of cyanobacterial toxins.16 For example, LC50 values 
of 10.8, 4.7 and 7.0 M have been measured for MC-LR, MC-YR and MC-RR, 
respectively.16 The low LC50 value of cyanopeptolin 1020 (1) thus clearly establishes 
that this compound constitutes another group of toxins in Microcystis of similar 
potency as several microcystins. Such toxicity might also be unveiled for other 
cyanopeptolins, and one related natural product from Planktothrix rubescens, 
oscillapeptin J, has been described of similar acute toxic activity.7 It can be speculated 
that these toxic effects are related to the very potent serine protease inhibition as 
described above, in particular as the large family of trypsin-like proteases17 are 
involved in many key processes related to the viability of organisms. More detailed 
toxicological studies on mammals are thus encouraged by this study. 
In this note, we have reported the structure elucidation of cyanopeptolin 1020 (1) 
extracted from Microcystis aeruginosa UV-006, which inhibits trypsin in the 
picomolar range and factor XIa and kallikrein in the low nanomolar range. This 
compound was shown to be toxic to the freshwater crustacean T. platyurus, and its 
toxicity was determined to be comparable to commonly found microcystins, which 
are frequently described as biotoxins from cyanobacteria. This report thus suggests 
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the presence of multiple toxins in Microcystis aeruginosa UV-006 and encourages 
further evaluation of toxicity of cyanopeptolin 1020 (1) in mammals. The co-
occurrence of toxic cyanopeptolin 1020 (1) along with several microcystins in 
Microcystis might also suggest a re-evaluation of drinking water guidelines and public 
health concerns currently solely focusing on microcystins to include other relevant 
toxins such as the presented cyanopeptolins as well. 
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Experimental Section 
General Experimental Procedures. NMR spectra were acquired on a Bruker 
DRX-600 equipped with a cryoprobe and are referenced to residual solvent proton 
and carbon signals (H 2.50, c 39.5 for DMSO-d6). Accurate mass ESI spectra were 
recorded on a Bruker FTMS 4.7T BioAPEX II at the University of Fribourg. The 
identification and the purification were performed on a HPLC Shimadzu 10AVP 
system equipped with a photodiode array detector RF-10AXL and an ESI mass 
spectrometric detector LCQ Duo (Finnigan Thermo). HPLC analyses for Marfey’s 
experiments were performed on a Dionex HPLC system equipped with a P680 pump, 
an ASI-100 automated sample injector, a TCC-100 thermostated column 
compartment, a PDA-100 photodiode array detector and a MSQ-ESI mass 
spectrometric detector.  
Culture, Extraction and Isolation. The Microcystis aeruginosa strain UV-006 
was an isolate from Hartebeespoort Dam near Pretoria, South Africa.11 M. aeruginosa 
UV-006 was grown in mineral medium at 26 °C under constant light conditions (40 ± 
5 µmol m-2 s-1). Glass tubes with a diameter of 7 cm and a height of 1.5 m containing 
5 L media were used. The tubes were aerated with 200 mL min-1 compressed air 
containing 1000 ppm CO2 and continuously stirred with a magnetic stirring bar. Cell 
biomass was harvested using a flow-through centrifuge (Westfalla Separator AG, 
Germany) and subsequently stored at -23 °C. To obtain high percentage labelled 
cyanopeptolin 1020 (1), nitrate was replaced by 15NO3- in the medium (final 
concentration 4.0 mM). 
Cyanopeptolin 1020 (1) was extracted by the addition of 10 ml 60% methanol per g 
of wet cell biomass, overnight incubation at 1 °C in the dark and centrifugation for 10 
min at 27500 × g. Compounds in the supernatant were brought to dryness in a rotatory 
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evaporator, dissolved in 2 ml 60% MeOH and filtered (0.2 µm pore size PTFE syringe 
filter). The solvent was removed under a moderate stream of nitrogen and the mixture 
was stored in glass vials at -23 °C. Compound 1 was then purified by HPLC with a 
reversed-phase column (C-18 Grom-Sil 120 ODS-4 HE, 250 x 4.6 mm, 5 µm particle 
size, Stagroma) with a flow rate of 1 ml min-1 and a column temperature of 30 °C. 
Separation and identification were performed with a binary solvent gradient of UV-
treated deionised H2O (solvent A) and CH3CN (solvent B), both acidified with 0.05% 
TFA (trifluoroacetic acid). The following gradient was used: 0 min: 30% B; 10 min: 
35% B; 40 min: 70% B, 42 min: 100% B; 50 min: 100% B; compound 1 eluted after 
13.0 min. TFA was removed before evaporating the solvents by applying sequentially 
the combined HPLC fraction on a C18 SPE cartridge (5 g, conditioned with 10% 
MeOH). The cartridge was then washed with H2O to remove TFA and 1 was finally 
eluted with 100% MeOH. Subsequently, the MeOH was removed under reduced 
pressure and H2O was removed by lyophilisation to afford 1 as a colourless 
amorphous solid. 
Cyanopeptolin 1020 (1): UV (47% acetonitrile in water with 0.05% TFA) max 277 
nm; 1H and 13C NMR data (DMSO-d6), see Table 1; HRESIFTMS m/z [M+H]
+ 
1021.5343 (calcd for C50H73N10O13, 1021.5353) 
 
Marfey’s Analysis. Compound 1 (0.1 mg, 0.1 mol) was hydrolyzed in a sealed 
tube with 6 N HCl (0.3 mL) at 105 °C for 24 h. The solution was concentrated to 
dryness with a stream of N2. The hydrolyzed compound was treated with 60 L of a 
solution of 1% N-(2,4-dinitro-5-fluorophenyl)-L-alaninamide (FDAA) in acetone 
and 60 L of 6% triethylamine in a sealed vial at 50 °C for 1 h. To the mixture 60 L 
of 5% acetic acid were added and the mixture was dried under a moderate stream of 
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N2. The residue was dissolved in 200 L of MeOH and analyzed by RP-HPLC using 
an Agilent Zorbax SB-C18 column (150 x 2.1 mm, 3.55 m). Mobile phase A was 
5% acetic acid in H2O, B was CH3CN / MeOH (9/1) and C was CH3CN. The linear 
gradient started with 5% B to reach 50% B over 50 min. The column was then washed 
for 10 min with 100% B, followed by 20 min with 100% C. The column was 
stabilized before the next injection with 5% B for 20 min and maintained at 50 °C.  
The flow rate was set at 0.2 mL / min. The configuration was determined by 
comparison with the retention time of derivatives from commercially available amino 
acids. The retention time for each amino acid derivative was obtained by extracting 
the mass of the derivative in the HPLC-MS chromatogram. Retention times (min) for 
the standard amino acid derivatives were determined as follows: L-Thr 25.2; L-allo-
Thr 26.4; D-Thr 32.3; D-allo-Thr 29.5; L-Arg 21.6; D-Arg 22.3; L-Phe 44.8; D-Phe 
50.1; L-Val 40.5; D-Val 46.7; L-N-Me-Tyr (di-FDAA derivative) 53.7; D-N-Me-Tyr 
(di-FDAA derivative) 54.4; L-Glu 27.6; D-Glu 30.8. The configuration of 
cyanopeptolin 1020 (1) was unambiguously assigned as L-Thr 24.9; L-Arg 21.6; L-
Phe 44.9; L-Val 40.0; L-N-Me-Tyr (di-FDAA derivative) 53.7 and L-Glu 27.6; see 
also the Supporting Information for chromatograms. 
Configuration of Ahp. The oxidation was realized according to the procedure 
developed by Itou et al.18 Cyanopeptolin 1020 (1 , 0.1 mg, 0.1 mol) was oxidized in 
a solution (0.5 mL) of CrO3 in AcOH (1 mg / mL) at room temperature for 2 hours. 
The mixture was then applied onto a C18 SPE cartridge conditioned with 10% MeOH. 
After applying the mixture, the cartridge was first washed with H2O, and the material 
was eluted with MeOH. After evaporation of the MeOH the resulting oxidized 
material was hydrolyzed, derivatized and analyzed as described above. Only the 
Marfey’s derivative of L-Glu was observed, thus establishing the configuration of 
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position 2 of the Ahp residue to be S; see also Supporting Information for 
chromatograms. 
Acute Toxicity Assay. The highly purified cyanopeptolin 1020 (1) was tested in a 
24 h acute toxicity assay with Thamnocephalus platyurus (Thamnotoxkit FTM; 
MicroBioTests Inc.) in a multiwell plate using instar II-III larvae hatched from cysts. 
The cyanopeptolin was tested in six concentrations ranging from 0.1 to 100 µM. For 
every concentration, 20 to 30 animals have been used. The nonlinear regression 
analysis and determination of the LC50 value were calculated with Graph Pad Prism 4 
for Windows. 
Protease Inhibition Assays. The details of the proteases and their respective 
fluorogenic substrates are summarized in Table S2. The enzyme inhibition assays 
were carried out in using modified literature procedures.19 The kinetic fluorescence 
measurements were realized with transparent microplates (Nunc) using a fluorescence 
microplate reader (Tecan infinite M1000) set at em = 355 nm, ex = 480 nm and 
measuring a datapoint every 30 seconds for 1 h. To obtain the initial reaction rate, 
linear regression was performed with Microsoft Excel. The enzymes were dissolved 
in a buffer containing 50 mM Tris-HCl pH 7.4, 100 mM NaCl, 10 mM MgCl2, 1 mM 
CaCl2, 0.1% BSA and 0.01% Triton X-100. To facilitate the dissolution of the 
substrates, 7.5% DMSO was added. The DMSO amended buffer was also used as 
blank. Optimal enzyme concentrations were determined by measuring kinetics with 
different enzyme concentration. The substrate solution (50 µL) was added to a 
mixture of 50 µL of the enzyme solution  and 50 µL of the blank. The enzyme 
concentrations were assayed between 0.1 and 10 nM (final concentration). The 
optimal protease concentrations are listed in Table S2. For the inhibition assays, a 
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mixture of 50 µL of protease solution and 50 µL of inhibitor solution were incubated 
at RT for 30 min. The substrate solution (50 µL) was then added and the measurement 
was directly started. The fractional activity was obtained by dividing the inhibited rate 
by the uninhibited rate obtained with a blank reaction. Chymotrypsin inhibition assays 
were performed as stated recently.7 The inhibition curves and the 50% inhibition 
values (IC50) were calculated using the non-linear regression sigmoidal four 
parameter formula with Prism 5.0b for Mac OS X. 
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C H (J in Hz) HMBC c ROESY 
HA 1 172.5, C    
 2 34.7, CH2 2.13, m HA-1, HA-3, HA-4  
 3 24.6, CH2 
a 1.51, m HA-1, HA-2, HA-4, HA-5 HA-4 
 4 30.5, CH2 1.23, m HA-5  
 5 21.6, CH2 1.27, m HA-4, HA-6  
 6 13.6, CH3 0.85, t (7.0, 7.0) HA-4, HA-5  
Glu 1 172.1, C    
 2 51.5, CH 4.39, ddd (9.1, 7.8, 
5.1) 




b 1.88, m 
1.73, m 
  
 4 30.0, CH2 2.26, m Glu-3, Glu-5 Glu-3a 
 5 173.9, C    
 NH  8.02, d (7.8) HA-1, Glu-2 Glu-2, Glu-3b, Glu-4, HA-2 
Thr 1 168.8, C    
 2 54.3, CH 4.57, d (9.3) Glu-1, Thr-1 Thr-4 
 3 71.7, CH 5.42, m Val-1, Thr-4 Thr-4 
 4 17.5, CH3 1.16, d (6.6) Thr-2, Thr-3  
 NH  7.85, d (9.3) Glu-1 Thr-2, Thr-4, Glu-2 
Arg 1 169.4, C    




b 1.88, m 
1.38, m 
 Arg-3b 
 4 24.6, CH2 
a 1.38, m   
 5 39.9, CH2 3.05, m   
 6 156.4, C    
 NH  8.49, d (8.9) Thr-1 Ahp-NH, Thr-2, Thr-3 
 NH2  7.46, m  Arg-5 
Ahp 1 168.6, C    
 2 48.4, CH 3.62, m Ahp-1 Ahp-3b, Ahp-3a, Ahp-4a 
 3a 
3b 













 5 73.5, CH 5.07, m Ahp-1 Ahp-4a, Ahp-4b, Phe-3a 
 NH  7.11, d (9.2) Arg-1 Ahp-2, Ahp-3a, Thr-3, Arg-2 
 OH  6.05, d (3.0)  Ahp-3a, Ahp-4a, Ahp-5, Val-5 
Phe 1 170.1, C    
 2 50.0, CH 4.75, dd (11.8, 3.7) Phe-1 Phe-3b 
 3a 
3b 
35.0, CH2 2.90, dd (13.9, 11.8) 




 1’ 136.5, C    
 2’/6’ 129.2, CH 6.84, d (7.3) Phe-3, Phe-2’/6’, Phe-5’ Phe-2, Phe-3a, Phe-3b, Ahp-4b,Ahp-2, Ahp-5 
 3’/5’ 127.5, CH 7.18, dd (7.3, 7.3) Phe-2’/6’, Phe-3’/5’, Phe-4’ Phe-2’/6’, N-Me-Tyr-2’/6’, N-Me-Tyr-3’/5’ 
 4’ 125.9, CH 7.14, d (7.3) Phe-2’/6’  
N-Me-
Tyr 
1 169.0, C    
 2 60.7, CH 4.89, dd (11.6, 2.3) N-Me-Tyr-1 N-Me-Tyr-3a, Phe-2 
 3a 
3b 
32.5, CH2 3.11, dd (14.2, 2.3) 




 1’ 127.3, C    
 2’/6’ 130.1, CH 7.00, d (8.4) N-Me-Tyr-3, N-Me-Tyr-2’/6’, 
N-Me-Tyr-4’ 
N-Me-Tyr-2, N-Me-Tyr-3’/5’, Phe-2, Phe-3a, 
Phe-3b 
 3’/5’ 115.1, CH 6.78, d (8.4) N-Me-Tyr-1’, N-Me-Tyr-3’/5’, 
N-Me-Tyr-4’ 
Ahp-OH (really weak) 
 4’ 156.0, C    
 NCH
3 
30.0, CH3 2.76, s Phe-1, N-Me-Tyr-2  
 OH  9.34, s N-Me-Tyr-3’/5’, N-Me-Tyr-4’ N-Me-Tyr-3’/5’ 
Val 1 171.8, C    
 2 55.5, CH 4.71, dd (9.6, 4.5) Val-1, Val-3, Val-5, N-Me-
Tyr-1 
Val-3, Val-4 





0.87, d (6.8) 
0.72, d (6.8) 
Val-2, Val-3, Val-5 
Val-2, Val-3, Val-4 
 
 NH  7.43, d (9.6) N-Me-Tyr-1 Val-2, Val-5, N-Me-Tyr-2, N-Me-Tyr-NCH3, 
Ahp-OH 
a b these two carbons can be interchanged, 
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